Drug Profile


Alternative Names: 19D12; SCH 717454; SCHOOL 717454

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Osteosarcoma; Sarcoma; Solid tumours

Most Recent Events

  • 01 Aug 2013 Merck terminates its phase II trial for Osteosarcoma or Ewing's sarcoma in USA, Canada, European Union & South Amercia (NCT00617890)
  • 15 Apr 2010 Merck completes enrolment in its phase I trial for Solid tumours in USA
  • 15 Dec 2009 Phase-II clinical trials in Solid tumours (combination therapy in adults) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top